
Omnicell is a publicly traded healthcare technology company (NASDAQ: OMCL) focused on pharmacy automation and medication management solutions for health systems and pharmacies. The company serves hospitals, health systems, and retail pharmacy customers with hardware, software, and services designed to improve medication safety and supply chain efficiency.
Tomer Stavitsky
Tomer Stavitsky is Senior Vice President and Chief Corporate Development Officer at Omnicell (NASDAQ: OMCL), where he leads corporate development and M&A strategy. He brings 15+ years of experience across healthcare, MedTech, digital health, AI, strategy, partnerships, and international M&A, with prior roles at Johnson & Johnson, Pfizer, Intuitive Surgical, ConvaTec, Ginkgo Bioworks, and Allurion. He has appeared on M&A Science to discuss M&A governance, deal teams, steering committees, and leading a deal from diligence through integration.
M&A Software for optimizing the M&A lifecycle- pipeline to diligence to integration
Explore dealroom

Want to wear your M&A expertise?
Check out the M&A Science store.




